Clinical Efficacy and Cost-Effectiveness of β-Lactam/β-Lactamase Inhibitor Combinations and Carbapenems in Liver Cirrhosis Patients with Gram-Negative Bacteria Bloodstream Infection

Clinical Efficacy and Cost-Effectiveness of β-Lactam/β-Lactamase Inhibitor Combinations and Carbapenems in Liver Cirrhosis Patients with Gram-Negative Bacteria Bloodstream Infection

Yuzhu Dong,1,* Ying Li,2,* Ying Zhang,1 Dan Sun,1 Qian Du,1 Tao Zhang,1 Mengmeng Teng,1 Ruiying Han,1 Yan Wang,3 Li Zhu,4 Jin’e Lei,5 Yalin Dong,1 Taotao Wang1 1Department of Pharmacy, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, People&...

Full description

Bibliographic Details
Main Authors: Dong Y, Li Y, Zhang Y, Sun D, Du Q, Zhang T, Teng M, Han R, Wang Y, Zhu L, Lei J, Wang T
Format: Article
Language:English
Published: Dove Medical Press 2020-05-01
Series:Infection and Drug Resistance
Subjects:
liver cirrhosis
gram-negative bacteria
bloodstream infection
efficacy
cost-effectiveness;
Online Access:https://www.dovepress.com/clinical-efficacy-and-cost-effectiveness-of-beta-lactambeta-lactamase--peer-reviewed-article-IDR

Internet

https://www.dovepress.com/clinical-efficacy-and-cost-effectiveness-of-beta-lactambeta-lactamase--peer-reviewed-article-IDR

Similar Items